Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland Schnell

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Hematological Oncology|May 4, 2021
Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic NeoplasmsWolfgang Knauf, Wolfgang Abenhardt, Michael Koenigsmann, et al.
International Journal of Cancer|July 9, 2004
Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivoBaerbel Matthey, Peter Borchmann, Roland Schnell, et al.
Journal of Bone Oncology|March 28, 2022
Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry studyAndreas Jakob, Mark-Oliver Zahn, Arnd Nusch, et al.
European Journal of Haematology|March 22, 2005
Imaging of central nervous system lymphomas with iodine-123 labeled rituximabMarkus Dietlein, Hendrik Pels, Holger Schulz, et al.
Haematologica|August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomasPeter Borchmann, Franck Morschhauser, Anne Parry, et al.
Blood|July 26, 2003
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphomaPeter Borchmann, John F Treml, Hinrich Hansen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibodyRoland Schnell, Markus Dietlein, Jan Oliver Staak, et al.
BMC Immunology|July 1, 2020
Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacementRudolf Weide, Roland Schnell, Christof Schardt, et al.
Blood|October 8, 2005
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivoElke Pogge von Strandmann, Hinrich P Hansen, Katrin S Reiners, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trialThomas Elter, Peter Borchmann, Holger Schulz, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Hematological Oncology|May 4, 2021
Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic NeoplasmsWolfgang Knauf, Wolfgang Abenhardt, Michael Koenigsmann, et al.
International Journal of Cancer|July 9, 2004
Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivoBaerbel Matthey, Peter Borchmann, Roland Schnell, et al.
Journal of Bone Oncology|March 28, 2022
Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry studyAndreas Jakob, Mark-Oliver Zahn, Arnd Nusch, et al.
European Journal of Haematology|March 22, 2005
Imaging of central nervous system lymphomas with iodine-123 labeled rituximabMarkus Dietlein, Hendrik Pels, Holger Schulz, et al.
Haematologica|August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomasPeter Borchmann, Franck Morschhauser, Anne Parry, et al.
Blood|July 26, 2003
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphomaPeter Borchmann, John F Treml, Hinrich Hansen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibodyRoland Schnell, Markus Dietlein, Jan Oliver Staak, et al.
BMC Immunology|July 1, 2020
Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacementRudolf Weide, Roland Schnell, Christof Schardt, et al.
Blood|October 8, 2005
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivoElke Pogge von Strandmann, Hinrich P Hansen, Katrin S Reiners, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2005
Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trialThomas Elter, Peter Borchmann, Holger Schulz, et al.
Pageof 3